EGA and Progenerika launch new study on value of generics
The European Generic and Biosimilar Medicines Association (EGA) and the German Generic and Biosimilar Medicines Association (Progenerika) today launched the IGES study in a joint press conference in Berlin.
This new study shows the value and contribution of generic medicines to society for three key therapeutic areas: hypertension, breast cancer and depression. The study notably shows that generic medicines have a positive impact on adherence for patients.
Generic competition increases the cost-effectiveness of therapy, thereby enabling physicians to treat many more patients than before. Generic competition also enables doctors to improve Quality Adjusted Life Years (QALYs) by reducing their cost (from around 50,000 euros [$53,650] to 7,200 euros [$7,726]), the report notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze